PRINCETON, N.J., Jan. 26, 2012 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com) ("BMR"), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with coverage of several small-cap med-tech stocks, including Align Technology (Nasdaq: ALGN), Zeltiq Aesthetics (Nasdaq: ZLTQ), Natus Medical (Nasdaq: BABY), Conceptus (Nasdaq: CPTS), ArthroCare (Nasdaq: ARTC) and Cardiovascular Systems (Nasdaq: CSII).
In addition to its daily newsletter and Recommended List of stocks, BMR publishes six earnings preview reports each quarter and several special reports each year. Its annual "High Yield" special report comes out before the new year, while its MLP special report comes out mid-year.
As a subscriber, you'll also gain access to our Recommended List of stocks, which from the start of 2008 until the end of 2011 was up 33.3%, compared with a -14.4% return for the S&P 500, a 47.7% outperformance.
Start your 14-day free trial today:
BMR looked at the following topics, among others:
-- Can Align continue its straight path of strong growth? Does the Cadent acquisition look like a good one?
-- Does Zeltiq Aesthetics look like it could be the next Intuitive Surgical (Nasdaq: ISRG) with its CoolSculpting procedure?
-- After a weak 2011, does Natus Medical look poised to get back on track in 2012?
-- Do ArthroCare and/or Conceptus look like solid turnaround candidates?
-- Does Cardiovascular Systems' treatment for peripheral artery disease (PAD) look like it will be a winner for investors?
Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.
NOTE: This release was published by Indie Research Advisors, LLC (CRD #131926), a registered investment advisor with the NASD and State of NJ. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Indie Research Advisors, LLC
Marcie Martin, +1-888-278-5515
SOURCE Indie Research Advisors, LLC